Compare CWT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | TRVI |
|---|---|---|
| Founded | 1926 | 2011 |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1997 | 2019 |
| Metric | CWT | TRVI |
|---|---|---|
| Price | $49.42 | $18.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $55.00 | $21.55 |
| AVG Volume (30 Days) | 444.2K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $963,695,000.00 | N/A |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $48.94 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $6.93 |
| 52 Week High | $53.82 | $20.22 |
| Indicator | CWT | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.